[
  {
    "ts": "2025-09-06T11:29:47+00:00",
    "headline": "How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story",
    "summary": "In August 2025, Regeneron Pharmaceuticals announced that its investigational siRNA therapeutic cemdisiran met both primary and key secondary endpoints in a Phase 3 trial for adults with generalized myasthenia gravis, highlighting clinical progress in its rare disease pipeline. This advance underscores Regeneron's momentum in developing next-generation treatments, adding to recent strong performances of core products and reflecting robust clinical execution. We'll examine how positive Phase 3...",
    "url": "https://finance.yahoo.com/news/positive-phase-3-cemdisiran-results-112947846.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "817f1436-4813-3257-9f2a-840282e1f60d",
      "content": {
        "id": "817f1436-4813-3257-9f2a-840282e1f60d",
        "contentType": "STORY",
        "title": "How Positive Phase 3 Cemdisiran Results at Regeneron (REGN) Have Changed Its Investment Story",
        "description": "",
        "summary": "In August 2025, Regeneron Pharmaceuticals announced that its investigational siRNA therapeutic cemdisiran met both primary and key secondary endpoints in a Phase 3 trial for adults with generalized myasthenia gravis, highlighting clinical progress in its rare disease pipeline. This advance underscores Regeneron's momentum in developing next-generation treatments, adding to recent strong performances of core products and reflecting robust clinical execution. We'll examine how positive Phase 3...",
        "pubDate": "2025-09-06T11:29:47Z",
        "displayTime": "2025-09-06T11:29:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/positive-phase-3-cemdisiran-results-112947846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/positive-phase-3-cemdisiran-results-112947846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]